NasdaqGS - Nasdaq Real Time Price USD

Roivant Sciences Ltd. (ROIV)

Compare
11.77 -0.01 (-0.08%)
As of 2:05 PM EDT. Market Open.
Loading Chart for ROIV
DELL
  • Previous Close 11.78
  • Open 11.77
  • Bid 11.76 x 100
  • Ask 11.80 x 100
  • Day's Range 11.67 - 11.82
  • 52 Week Range 8.24 - 13.24
  • Volume 1,070,108
  • Avg. Volume 4,983,214
  • Market Cap (intraday) 8.704B
  • Beta (5Y Monthly) 1.24
  • PE Ratio (TTM) 2.05
  • EPS (TTM) 5.73
  • Earnings Date Nov 11, 2024 - Nov 15, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 16.75

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.

roivant.com

908

Full Time Employees

March 31

Fiscal Year Ends

Recent News: ROIV

View More

Performance Overview: ROIV

Trailing total returns as of 8/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ROIV
4.81%
S&P 500
18.04%

1-Year Return

ROIV
5.66%
S&P 500
27.79%

3-Year Return

ROIV
18.53%
S&P 500
25.95%

5-Year Return

ROIV
12.10%
S&P 500
52.07%

Compare To: ROIV

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ROIV

View More

Valuation Measures

Annual
As of 8/26/2024
  • Market Cap

    8.72B

  • Enterprise Value

    3.42B

  • Trailing P/E

    2.06

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    62.28

  • Price/Book (mrq)

    1.60

  • Enterprise Value/Revenue

    21.58

  • Enterprise Value/EBITDA

    0.73

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2,991.76%

  • Return on Assets (ttm)

    -15.03%

  • Return on Equity (ttm)

    127.71%

  • Revenue (ttm)

    158.3M

  • Net Income Avi to Common (ttm)

    4.74B

  • Diluted EPS (ttm)

    5.73

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.68B

  • Total Debt/Equity (mrq)

    6.43%

  • Levered Free Cash Flow (ttm)

    -645.15M

Research Analysis: ROIV

View More

Company Insights: ROIV

Research Reports: ROIV

View More

People Also Watch